Navigation Links
Elan Pharmaceuticals Joins GeneGo's MetaTox Consortium
Date:11/27/2007

ST. JOSEPH, Mich., Nov. 27 /PRNewswire/ -- GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Elan Pharmaceuticals has joined the MetaTox Consortium. The Consortium, led by Dr. Richard Brennan, will be focused on developing systems biology tools for safety assessment of small molecule compounds and biological therapeutics. This effort will include expanding the existing tools in the MetaDiscovery(TM) platform with toxicity ontologies, developing "knowledge-based" predictive models (functional descriptors), manual reconstruction of toxicity pathways in human and relevant preclinical model species, and the development of simplified workflows for analyzing and reporting systems toxicology data. These tools, unique to the marketplace, will enable the members to leverage their diverse molecular toxicology data in an integrated "systems" perspective that has not been available until now.

"The MetaTox Consortium is a cost effective vehicle for the members to develop software and expand content in systems toxicology," said Julie Bryant, Vice President of Business Development for GeneGo. "The Consortium will propose the deliverables, to be voted on and prioritized by the members, and GeneGo will then develop and deliver the agreed-upon content and software with members' input. All the members joining to date have said that they could not perform this amount of work internally for the membership fee, which helped to justify the business model."

"Despite the increasing deployment of new technologies probing the molecular basis of chemical toxicity, too many investigational drugs still fail in clinical trials due to human toxicity unseen in pre-clinical safety assessment", said Dr. Richard Brennan, Director of Toxicology at GeneGo, "The Consortium, which includes representatives from industry and from FDA, believes that part of the problem lies in a lack of appropriate data analysis tools to properly integrate the multiple data types generated by data-rich 'omics technologies, and to convert findings from cell-based and animal models into meaningful human risk-assessments. We will focus on developing novel predictive models, while expanding our knowledge-base of toxicity information, and developing new software for 'omics data analysis in a systems biology perspective. Alongside GeneGo's expertise in identifying and mapping differences in human and model-species biology, these tools will facilitate a better assessment of the potential for human toxicity from preclinical tests, increasing the quality of, and confidence in, new compounds going into clinical trials. They will also contribute to understanding the causes of failure for compounds that drop out of trials, or are withdrawn from the market, for safety reasons, allowing these liabilities to be screened out of follow-up molecules."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... California Senate ... medical payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ ... Research Institute (WCRI) . , According to the study, medical payments per claim in ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael ... headquartered in Hamilton County, is embarking on a charity drive with the aim ... new homes for orphaned or neglected senior dogs in the Cincinnati region, and ...
(Date:12/8/2016)... Fort Payne, AL (PRWEB) , ... December 08, ... ... enterprise offering insurance and financial consulting services to residential and commercial clients in ... raise awareness and support for Nobis Works. , Since 1977, Nobis Works has ...
(Date:12/7/2016)... Wisconsin (PRWEB) , ... December 07, 2016 , ... Kenall ... extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire ... right amount of light where and when it’s needed. , A 2’ ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... (“Presence”) for a purchase price of approximately $17.4 million (net of the ... revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is a ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... N.J., Dec. 8, 2016 CANTEL MEDICAL CORP. (NYSE: ... of $18,800,000, or $0.45 per diluted share, on a 22.1% ... quarter ended October 31, 2016. This compares with net income ... $153,779,000 for the first quarter ended October 31, 2015. ... quarter ended October 31, 2016 to $21,323,000, or $0.51 per ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech Pte ... the Genome Institute of Singapore (GIS) ... joint venture between Novogene and AITbiotech – will establish a ... Singapore .   The new centre will ...
(Date:12/7/2016)... Dec. 7, 2016   IQuity, Inc., a ... Don Hardison has been appointed to ... executive with extensive experience as CEO, COO, and ... 500 companies within the molecular, clinical diagnostic, and ... and sales experience within the pharmaceutical industry. His ...
Breaking Medicine Technology: